DFE Pharma appoints Martti Hedman as new CEO

DFE Pharma appoints Martti Hedman as new CEO

The combination of his experience, culture and drive makes him an ideal fit for
DFE Pharma for the next stages of growth

Goch, Germany (7^th February 2022) – DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, today announced that Martti Hedman has been appointed as the new Chief Executive Officer. An experienced business leader, Hedman will succeed Bas van Driel and assume responsibilities on 14^th February. Van Driel decided to step down in order to allow the company to further grow after setting the company up for success.

Hedman has many years of global business leadership experience in the pharma industry, having lived and held executive positions in the United States, United Kingdom, Germany, and Finland. As former CEO of Colorcon, a global designer and developer of specialty excipients for solid oral dosages for the pharmaceutical and nutritional industries, he is well-known to the industry.

Speaking on behalf of the Governance Board, Herman Ermens of Royal FrieslandCampina, said: “We are very pleased to welcome Martti Hedman to DFE Pharma, an influential and decisive leader with a history of success. Martti will bring a wealth of international experience in the pharma industry as well as a broad range of both industry and customer relationships. We are confident that Martti is very well-placed to take the business to the next level as a global excipient company.”

“I am excited to join DFE Pharma as its new CEO. The company is a global market leader in its excipient categories. I am looking forward to working with all my new colleagues and taking the company to the next phase. I am especially pleased to know that DFE Pharma plays a key role in the COVID-19 therapies – both in vaccines and in solid oral dosage forms”, Hedman adds.

-END-

About DFE Pharma

DFE Pharma is a global leader in pharma- and nutraceutical excipient solutions. We strive to develop, produce and supply the highest quality functional excipients for use in the pharmaceutical, biopharmaceutical and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations. Our excipients are used in numerous medicinal and nutraceutical products, including COVID-19 vaccines and - treatments.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients for release in a predictable and effective manner into the patient’s system. With more than a century of experience and around 450 people worldwide, we are serving over 5,000 customers in 100+ countries worldwide. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies in their journey to improve patients’ lives, driven by our purpose your medicines, our solutions. Moving to a healthier world.

Learn more at www.dfepharma.com or follow us on social media.

--------------------------

Media Contact:  

Amanda Leweson - Discovery PR, on behalf of DFE Pharma 

Email: amanda@discovery-pr.com    

Mobile: + 44 (0) 7852 153 791    

Office:   +44 (0) 1606 889 194